Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro

Tissue Engineering

Volumn 13, Issue 1, 2007, Pages 111-121

  Niemeyer, Philipp ^a,c   Kornacker, Martin ^b   Mehlhorn, Alexander ^a   Seckinger, Anja ^b   Vohrer, Jana ^a   Schmal, Hagen ^a   Kasten, Philip ^b   Eckstein, Volker ^b   Südkamp, Norbert P ^a   Krause, Ulf ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; BIOMEDICAL ENGINEERING; BONE; CELLS; MUSCULOSKELETAL SYSTEM; TISSUE;

ALLOGENIC TRANSPLANTATION; BONE MARROW STROMAL CELLS; TISSUE-DERIVED STEM CELLS;

IMMUNOLOGY;

CD40 ANTIGEN; CD40 LIGAND; CELL MARKER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE ANTIGEN;

ADIPOSE TISSUE CELL; BONE DEVELOPMENT; BONE MARROW CELL; CELL DIFFERENTIATION; CELL ISOLATION; COCULTURE; CONFERENCE PAPER; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MIXED LYMPHOCYTE CULTURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; T LYMPHOCYTE; TISSUE ENGINEERING;

ADIPOSE TISSUE; ANTIGENS, CD; BONE MARROW CELLS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELLS, CULTURED; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUKOCYTES, MONONUCLEAR; MESENCHYMAL STEM CELLS; OSTEOGENESIS; STROMAL CELLS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 33846594229     PISSN: 10763279     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.2006.0114     Document Type: Conference Paper

References (43)

1. Cancedda R., Mastrogiacomo M., Bianchi G., Derubeis A., Muraglia A., Quarto R., Gugala Z., Gogolewski S., Kon E., Corsi A., Bianco P., Marcacci M., Martin I., Boyde A., Ruspantini I., Chistolini P., Rocca M., Giardino R., Zaffagnini S. and Benvenuti A. Bone marrow stromal cells and their use in regenerating bone. Novartis Found Symp 249, 133, 2003.
2. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S. and Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143, 1999.
3. Caplan A.I. Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. Tissue Eng 11, 1198, 2005.
4. Mauney J.R., Volloch V. and Kaplan D.L. Role of adult mesenchymal stem cells in bone tissue engineering applications: current status and future prospects. Tissue Eng 11, 787, 2005.
5. Reyes M., Lund T., Lenvik T., Aguiar D., Koodie L. and Verfaillie C.M. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 98, 2615, 2001.
6. Zuk P.A., Zhu M., Ashjian P., De Ugarte D.A., Huang J.I., Mizuno H., Alfonso Z.C., Fraser J.K., Benhaim P. and Hedrick M.H. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13, 4279, 2002.
7. Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J., Benhaim P., Lorenz H.P. and Hedrick M.H. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7, 211, 2001.
8. Erices A., Conget P. and Minguell J.J. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 109, 235, 2000.
9. Mareschi K., Biasin E., Piacibello W., Aglietta M., Madon E. and Fagioli F. Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. Haematologica 86, 1099, 2001.
10. Kern S., Eichler H., Stoeve J., Kluter H. and Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood or adipose tissue. Stem Cells published online Jan 12, 2006.
11. Wagner W., Wein F., Seckinger A., Frankhauser M., Wirkner U., Krause U., Blake J., Schwager C., Eckstein V., Ansorge W. and Ho A.D. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 33, 1402, 2005.
12. Puissant B., Barreau C., Bourin P., Clavel C., Corre J., Bousquet C., Taureau C., Cousin B., Abbal M., Laharrague P., Penicaud L., Casteilla L. and Blancher A. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 129, 118, 2005.
13. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A. and Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30, 42, 2002.
14. Dean R.M. and Bishop M.R. Graft-versus-host disease: emerging concepts in prevention and therapy. Curr Hematol Rep 2, 287, 2003.
15. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E. and Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31, 890, 2003.
16. Bach F.H. The major histocompatibility complex in transplantation immunology. Transplant Proc 5, 23, 1973.
17. Rothstein D.M. and Sayegh M.H. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 196, 85, 2003.
18. Chen J.L., Guo Z.K., Xu C., Li Y.H., Hou C.M., Mao N. and Chen H. [Mesenchymal stem cells suppress allogeneic T cell responses by secretion of TGF-beta1]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 10, 285, 2002.
19. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E. and Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57, 11, 2003.
20. Rasmusson I., Ringden O., Sundberg B. and Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76, 1208, 2003.
21. Ammann P., Shen V., Robin B., Mauras Y., Bonjour J.P. and Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 19, 2012, 2004.
22. Erickson G.R., Gimble J.M., Franklin D.M., Rice H.E., Awad H. and Guilak F. Chondrogenic potential of adipose tissue-derived stromal cells in vitro and in vivo. 290, 763, 2002.
23. Estes B., Diekmann B., Kreuzer S., Fermor B. and Guilak F. The influence of culture conditions and cell shape of chondrogenic potential of adipose derived adult stem cells. Conference proceedings of the 51st Annual Meeting of the Orthopaedic Research Society 2005, Poster 0970, Washington, DC, 2005.
24. Hundemer M., Schmidt S., Condomines M., Lupu A., Hose D., Moos M., Cremer F., Kleist C., Terness P., Belle S., Ho A.D., Goldschmidt H., Klein B. and Christensen O. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol 34, 486, 2006.
25. Tarte K., Fiol G., Rossi J.F. and Klein B. Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia 14, 2182, 2000.
26. Kornacker M., Verneris M.R., Kornacker B., Scheffold C. and Negrin R.S. Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett 76, 169, 2001.
27. Niemeyer P., Seckinger A., Simank H.G., Kasten P., Sudkamp N. and Krause U. [Allogenic transplantation of human mesenchymal stem cells for tissue engineering purposes: an in vitro study]. Orthopade 33, 1346, 2004.
28. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S. and Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838, 2002.
29. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., Santarlasci V., Mazzinghi B., Pizzolo G., Vinante F., Romagnani P., Maggi E., Romagnani S. and Annunziato F. Role for IFN-{gamma} in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2005.
30. Aggarwal S. and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815, 2005.
31. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G. and Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106, 1755, 2005.
32. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., Risso M., Gualandi F., Mancardi G.L., Pistoia V. and Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood 107, 367, 2006.
33. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C. and Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107, 1484, 2006.
34. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D. and Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105, 4120, 2005.
35. De Kok I.J., Peter S.J., Archambault M., van den Bos C., Kadiyala S., Aukhil I. and Cooper L.F. Investigation of allogeneic mesenchymal stem cell-based alveolar bone formation: preliminary findings. Clin Oral Implants Res 14, 481, 2003.
36. Arinzeh T.L., Peter S.J., Archambault M.P., van den Bos C., Gordon S., Kraus K., Smith A. and Kadiyala S. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am 85-A, 1927, 2003.
37. Makkar R.R., Price M.J., Lill M., Frantzen M., Takizawa K., Kleisli T., Zheng J., Kar S., McClelan R., Miyamota T., Bick-Forrester J., Fishbein M.C., Shah P.K., Forrester J.S., Sharifi B., Chen P.S. and Qayyum M. Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction. J Cardiovasc Pharmacol Ther 10, 225, 2005.
38. Schoeberlein A., Holzgreve W., Dudler L., Hahn S. and Surbek D.V. Tissue-specific engraftment after in utero transplantation of allogeneic mesenchymal stem cells into sheep fetuses. Am J Obstet Gynecol 192, 1044, 2005.
39. Sato Y., Araki H., Kato J., Nakamura K., Kawano Y., Kobune M., Sato T., Miyanishi K., Takayama T., Takahashi M., Takimoto R., Iyama S., Matsunaga T., Ohtani S., Matsuura A., Hamada H. and Niitsu Y. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 106, 756, 2005.
40. Grinnemo K.H., Mansson A., Dellgren G., Klingberg D., Wardell E., Drvota V., Tammik C., Holgersson J., Ringden O., Sylven C. and Le Blanc K. Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg 127, 1293, 2004.
41. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., Noel D. and Jorgensen C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102, 3837, 2003.
42. Zhu W., Xu W., Jiang R., Qian H., Chen M., Hu J., Cao W., Han C. and Chen Y. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 80, 267, 2006.
43. Riggi N., Cironi L., Provero P., Silva M.L., Kaloulis K., Garcia-Echeverria C., Hoffmann F., Trumpp A. and Stamenkovic I. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65, 11459, 2005.